Caricamento...
Mechanisms of resistance to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors (‘targeted therapies’) largely...
Salvato in:
| Pubblicato in: | Br J Cancer |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5765236/ https://ncbi.nlm.nih.gov/pubmed/29319049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.434 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|